E P H K Pharmaceutical Import Profile — Hungary (DGFT 2022–2026)

Name: E P H K Pharmaceutical Import Records from India — 4 Products, $1.5M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

E P H K — Pharmaceutical Importer Profile (2026) | 4 Products, $1.5M Trade | TransData Nexus

E P H K

Pharmaceutical Importer · Hungary · Advanced Antibiotics Focus · $1.5M Total Trade · DGFT Verified

E P H K is a pharmaceutical importer based in Hungary with a total trade value of $1.5M across 4 products in 2 therapeutic categories. Based on 33 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. E P H K sources from 1 verified Indian supplier, with Venus Remedies Limited accounting for 100.0% of imports.

E P H K — Import Portfolio & Supplier Network

E P H K import network — 4 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to E P H K?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Venus Remedies Limited	$2.0M	67	100.0%

E P H K sources from 1 verified Indian supplier across 59 distinct formulations. The sourcing is highly concentrated — Venus Remedies Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

What Formulations Does E P H K Import?

Formulation	Value	Ships
Meropenem 1.0 GM powder for solution forinjection or infusion(meropenem venus pharma 1 GM)	$150.0K	3
Meropenem 1.0 GM powder for solution forinjection or infusion(meropenem venus pharma 1.0 GM)	$146.1K	3
Meropenem 1.0 GM powder for solution forinjection or infusion (meropenem venuspharma 1 GM)	$100.0K	2
Bleomycin for injection (15 IU) Each vial contains: bleomycin sulphate equivalent to bleomycin... 15 IU	$95.9K	2
Meropenem 1.0 GM powder for solution forinjection or infusion ((meropenem venuspharma 1 GM)	$50.0K	1
Meropenem 1.0 GM powder for solution forinjection or infusioneach vial contains: active pharmaceutical ingredients	$50.0K	1
Meropenem 500 MG powder for solution forinjection or infusion Each vial contains: active pharmaceutical ingredients	$50.0K	1
Cisplatin venus pharma 100MG/100ML(cisplatin concentrate for solution for infusion 100MG/100ML)	$50.0K	1
Meropenem 1.0 GM powder for solution forinjection or infusion. meropenem 1000 MG.	$50.0K	1
Meropenem 500 MG powder for solution forinjection or infusion (meropenem venus500 MG)	$50.0K	1
Meropenem 1.0 GM powder for solution forinjection or infusion (meropenem 1GM)	$50.0K	1
Ceftriaxone powder for solution for injection 2000 MG (ceftriaxone 2.0 GM)	$50.0K	1
Meropenem 1.0 GM powder for solution forinjection or infusion (meropenem venuspharma 1000MG)	$50.0K	1
Ceftazidime powder for solution for injection or infusion 2.0 g (ceftazidime venus pharma 2.0 GM)	$50.0K	1
Bortezomib powder for solution for injection 3.5 MG bortezomib bioteach pharma limited 3.5MG	$50.0K	1

Import Portfolio — Top 4 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Meropenem	Advanced Antibiotics	$1.2M	24	0.5%	9
2	Ceftazidime	Advanced Antibiotics	$174.3K	4	1.6%	5
3	Bleomycin	Advanced Oncology	$100.0K	2	1.8%	8
4	Topotecan	Advanced Oncology	$59.2K	3	1.6%	13

E P H K imports 4 pharmaceutical products across 2 categories into Hungary totaling $1.5M.

E P H K — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

E P H K is a pharmaceutical importer and buyer based in Hungary, specializing in the acquisition of finished pharmaceutical formulations from international suppliers. The company plays a pivotal role in Hungary's pharmaceutical distribution network, ensuring the availability of essential medications across the country. While specific details about its headquarters and parent company are not publicly disclosed, E P H K's operations are integral to the Hungarian healthcare system, facilitating the importation and distribution of critical pharmaceutical products.

2Distribution Network

E P H K's distribution network encompasses multiple warehouse locations strategically situated to optimize logistics and ensure timely delivery of pharmaceutical products throughout Hungary. The company's logistics capabilities are robust, enabling efficient handling, storage, and transportation of a diverse range of medications. Geographically, E P H K's coverage extends across Hungary, with potential outreach to neighboring countries, thereby enhancing the accessibility of imported pharmaceutical products to a broader European market.

3Industry Role

Within Hungary's pharmaceutical supply chain, E P H K functions primarily as an importer and distributor of finished pharmaceutical formulations. The company sources a variety of medications from international suppliers, including a significant volume from India, and facilitates their entry into the Hungarian market. By doing so, E P H K ensures that a wide array of pharmaceutical products is available to meet the needs of healthcare providers and patients across the country.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — E P H K

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

E P H K's sourcing strategy exhibits a high degree of concentration, with a total import value of $1.5 million USD from India over 33 shipments, all sourced from a single supplier, Venus Remedies Limited. This single-source dependency may pose risks related to supply chain disruptions, such as potential delays or quality control issues. However, the consistent volume and frequency of shipments suggest a stable and well-established relationship between E P H K and Venus Remedies Limited, indicating a strategic choice to maintain a reliable supply chain.

2Supply Chain Resilience

E P H K's supply chain resilience is closely tied to its exclusive partnership with Venus Remedies Limited. The lack of backup suppliers and the concentration on a single supplier may expose the company to risks associated with supply chain disruptions. Additionally, the limited diversity in imported formulations, with 59 unique formulations, could impact the company's ability to adapt to changing market demands. The resilience of the supply chain is further influenced by the shipping routes and the regulatory compliance of Venus Remedies Limited, which must adhere to international standards to ensure uninterrupted supply.

3Strategic Implications

Importing Pharmaceuticals into Hungary — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Hungary

1Regulatory Authority & Framework

In Hungary, the National Institute of Pharmacy and Nutrition (OGYÉI) serves as the primary regulatory authority overseeing pharmaceutical imports. The regulatory framework governing pharmaceutical imports is primarily defined by the Medicines Thrift Act (Act XCVIII of 2006) and the Medicinal Products Act (Act XCV of 2000). These acts implement European Union directives and international regulations, establishing comprehensive guidelines for the importation, distribution, and marketing of medicinal products in Hungary. The Medicines Thrift Act focuses on the reliable and economically feasible supply of medicinal products, while the Medicinal Products Act addresses the registration, clinical trials, and wholesale distribution of medicines. (cms.law)

2Import Licensing & GMP

Import licensing in Hungary requires compliance with Good Manufacturing Practice (GMP) standards, which are recognized by the European Union and the World Health Organization. Importers must obtain the necessary licenses from OGYÉI, ensuring that imported pharmaceutical products meet stringent quality and safety standards. Additionally, wholesale distribution authorization is mandatory for entities involved in the distribution of medicinal products, ensuring that all stages of the pharmaceutical supply chain adhere to regulatory requirements. (ogyei.gov.hu)

E P H K — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

E P H K's focus on importing advanced antibiotics and oncology medications aligns with the growing demand for specialized treatments in Hungary. The substantial import value of meropenem and ceftazidime indicates a strategic emphasis on addressing critical healthcare needs in the country. The inclusion of oncology medications like bleomycin and topotecan reflects a commitment to providing comprehensive treatment options for cancer patients. This product strategy positions E P H K as a key player in supplying essential and specialized pharmaceutical products to the Hungarian market.

2Sourcing Profile

E P H K's sourcing strategy is centered on importing generic drugs from India, focusing on finished pharmaceutical formulations. The company's preference for formulations that meet EU GMP standards ensures compliance with regulatory requirements and maintains product quality. India's established pharmaceutical manufacturing capabilities and cost-effectiveness make it a strategic partner for E P H K, enabling the company to offer a diverse range of medications to the Hungarian market.

3Market Positioning

E P H K serves a critical segment of the Hungarian pharmaceutical market by supplying advanced antibiotics and oncology medications. The company's product mix caters to both hospital and retail pharmacy sectors, ensuring that healthcare providers and patients have access to essential and specialized treatments. By focusing on these therapeutic areas, E P H K positions itself as a key supplier of critical medications, contributing to the overall health and well-being of the Hungarian population.

Seller's Guide — How to Become a Supplier to E P H K

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to collaborate with E P H K, especially in the oncology segment, where the company imports a limited number of products. Introducing a broader range of oncology medications could enhance E P H K's product portfolio and meet the growing demand for cancer treatments in Hungary. Additionally, diversifying the supplier base could mitigate risks associated with single-source dependency and strengthen the resilience of E P H K's supply chain.

2Requirements & Qualifications

Indian exporters seeking to supply E P H K and the Hungarian market must ensure that their products comply with EU GMP standards and obtain the necessary marketing authorizations from OGYÉI. Products must undergo batch testing and meet stability requirements to ensure safety and efficacy. Labeling must be in Hungarian, providing clear and accurate information about the product. Additionally, exporters must adhere to serialization mandates to prevent counterfeit products and ensure traceability throughout the supply chain.

3How to Approach

Frequently Asked Questions — E P H K

What products does E P H K import from India?

E P H K imports 4 pharmaceutical products across 2 categories. Top imports: Meropenem ($1.2M), Ceftazidime ($174.3K), Bleomycin ($100.0K), Topotecan ($59.2K).

Who supplies pharmaceuticals to E P H K from India?

E P H K sources from 1 verified Indian suppliers. The primary supplier is Venus Remedies Limited (100.0% of imports, $2.0M).

What is E P H K's total pharmaceutical import value?

E P H K's total pharmaceutical import value from India is $1.5M, based on 33 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does E P H K focus on?

E P H K imports across 2 categories. The largest: Advanced Antibiotics (89.6%), Advanced Oncology (10.4%).

Get Full E P H K Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.